RGCC International

03/09/2026

Starting can feel overwhelming, but having the right information beforehand can make all the difference.

RGCC's ChemoSNiP test analyses a patient's genetic profile to predict how they are likely to respond to specific drugs, such as chemotherapy agents, helping clinicians identify the most effective and least toxic treatment options before therapy even begins.

ChemoSNiP is recommended for:
🧬 Cancer patients preparing to begin chemotherapy or targeted drug treatment
⚕️ Patients who have experienced limited success or high toxicity with previous therapies
👨‍⚕️ Clinicians seeking to optimise treatment plans based on pharmacogenomic insights

Learn more about ChemoSNiP and how it is helping to advance precision oncology:
👉 rgcc-international.com/tests/chemosnip/

01/09/2026

After overcoming cancer at 20 and again at 40, one patient faced a third diagnosis in her 60s, this time with stage 4 metastatic breast .

Through a personalized treatment strategy combining precision , targeted therapies, and robotic surgery, her care team achieved an extraordinary outcome: complete response with no viable cancer cells detected.

RGCC’s test played an important role in the patient’s journey by helping Dr Mandeep Singh Malhotra and his team better understand the biology of her cancer and identify treatment options tailored to her specific condition. This personalized approach supported more informed treatment decisions while prioritizing patient safety.

Today, the patient is disease-free, a powerful example of how precision medicine and advanced diagnostics continue to transform cancer care.

Read the full case study:

At the age of 20, she was diagnosed with cancer for the first time. Again, at 40, she faced another cancer diagnosis. Now, at 60, she has encountered cancer

25/08/2026

📢 New peer-reviewed research from the team is now published in the International Journal of Molecular Sciences.

Our scientists investigated the impact of the microenvironment on cancer cells by comparing traditional cell culture versus a 3D collagen-based system that more closely mimics physiological conditions in vitro. Next to phenotypical differences, the findings show that the collagen microenvironment has a cell-specific impact on the whole transcriptome, both qualitatively and quantitatively. This significant transcriptional reprogramming points to essential changes in gene regulatory networks that affect cancer cell behavior — changes worth considering for downstream applications.
This matters because it reinforces why physiologically relevant models are so important for understanding biology and developing better treatments.

📖 Read the full study: https://rgcc-international.com/published-articles/mpdi-2026/

20/08/2026

Our test is a cutting-edge pharmacogenomic blood test that helps clinicians gain powerful insights into how a patient’s unique genetic profile influences drug metabolism, ensuring more precise and effective cancer treatment planning. It supports by:

🧬Determining which medications are likely to be most effective for a specific patient
🧬Providing detailed insights on how drugs are metabolized to prevent excessive toxicity
🧬Pinpointing the best possible drug combinations for safe and effective therapy

Learn more: rgcc-international.com/tests/chemosnip/

16/08/2026

Our sister company, Welmedis, is dedicated to identifying groups of patients with limited effective treatment options and developing targeted therapies tailored to their specific cancer profiles.

Explore their ongoing research and development projects on the pipeline:
🔬

Pipeline At Welmedis, we focus on identifying groups of cancer patients with limited effective treatment options and developing targeted therapies tailored to their specific cancer profiles. Our pipeline showcases ongoing research and development projects, highlighting their current status and field...

12/08/2026

Have you read the recently published study from our research team?

How long can a cancer cell line be cultured before its gene expression starts to drift, and why does it matter for research? Our scientists at Central Europe investigated exactly that. By tracking the transcriptomic profile of HCT-116 colon cancer cells over 25 passages (~16 weeks), they found that gene expression remained largely stable up to passage 15. Beyond that point, genes linked to cell proliferation and cell death began to shift - changes that could affect how cells respond to therapies and compromise experimental reproducibility.

The takeaway: passage number is not a minor detail. It's a variable that can fundamentally influence research outcomes.

This work reinforces our commitment to rigorous, reproducible science and to understanding biology at the molecular level.

🔗 Read the full open-access article: https://www.micropublication.org/journals/biology/micropub-biology-002074

06/08/2026

📢 We're proud to announce that International has signed a Memorandum of Understanding with Genomik Solidaritas Indonesia (GSI Lab) to establish a comprehensive cancer diagnostics center of excellence in Indonesia, combining GSI's local infrastructure with RGCC's scientific expertise.

The collaboration will introduce and scale advanced diagnostic services in Indonesia, including:
🔬 ctDNA analysis
🔬 Tumor tissue genomic profiling via NGS panels
🔬 Functional Circulating Tumor Cell (CTC) analysis

The agreement was formally presented to H.E. Mr. Febrian Alphyanto Ruddyard, Vice Minister of National Development Planning of the Republic of , reflecting the Indonesian Government's strong support for advancing precision medicine and molecular diagnostics in the region.

Read the full announcement here:

RGCC International and GSI have signed an MOU to advance precision oncology and cancer diagnostics in Indonesia, backed by the Indonesian Government.

01/08/2026

Today marks World Lung Cancer Day, a moment to raise awareness, honor those affected, and reaffirm our commitment to advancing cancer science.

Lung cancer remains the leading cause of cases and deaths worldwide, with an estimated 2.5 million new cases and 1.8 million deaths recorded in 2022 alone. Yet the majority of cases are preventable, with to***co smoking accounting for 60–70% of cases, followed by air pollution and occupational exposure.

One of the greatest challenges is that lung cancer is often diagnosed at advanced stages, when treatment options become more limited. Early screening of high-risk individuals has the potential to change this, dramatically improving survival outcomes and saving lives.

At RGCC, we believe that personalized, science-driven diagnostics play a vital role in detecting cancer earlier and supporting more informed treatment decisions.

🫁 Visit our patient information page to learn more about lung cancer:

Our experts provide comprehensive insights into therapy methods for lung cancer such as surgery, chemotherapy, radiotherapy & new personalized treatments.

27/07/2026

What if a simple blood draw could tell you exactly which treatments work against each patient's ?
That's the power of RGCC testing, and it's why physicians like Jesse Morse, M.D. are recommending it to their patients.
Our blood tests help identify circulating cells (CTCs), cancer markers in the blood, and tumor-specific genetic characteristics associated with malignant tumors.

🔗 Learn more about RGCC testing: https://eu1.hubs.ly/H0wDXsQ0
🔗 Read more testimonials: https://eu1.hubs.ly/H0wDXsQ0

22/07/2026

📢 New publication from our Central Europe research team!

SHMT (serine hydroxymethyltransferase) has emerged as a promising target in cancer research due to its role in the metabolic pathways that fuel growth. Yet comprehensive biochemical data on SHMT inhibitors has remained a gap in the literature.
In this newly published study in RSC Advances, our scientists present the first application of an enzymatic assay, in which the SHMT reaction is coupled to the enzyme alcohol dehydrogenase, to evaluate the activity of SHMT inhibitors — thereby providing missing data by using a new methodological and cost-effective approach that opens up new avenues for future drug discovery.

📄 Read the full open-access article:https://rgcc-international.com/wp-content/uploads/Article-SHMT-inhibitor-RGCC-CE.pdf